Primagen Holding B.V.

Primagen Holding B.V. is a privately held company headquartered in Amsterdam, The Netherlands. Primagen designs, develops and commercializes molecular tests that have high, individualized predictive value and improve the quality of life for patients suffering from life-threatening diseases, such as infections, AIDS and cancer. Primagen's success is built on a unique combination of an international scientific network and excellent capabilities for product development, manufacturing and marketing. The company is solution-driven and selects those leads for potential products in which proprietary intellectual property can be leveraged rapidly from bench to market. Primagen has two marketed molecular product lines; Retina(TM) Mitox products measure mitochondrial DNA and RNA in clinical samples with unmatched accuracy and predict the onset of clinical symptoms as a result of mitochondrial toxicity. The Retina(TM) Rainbow product enables detection of all circulating HIV-1 subtypes and combined with Primagen's proprietary dried bloodspot filter paper technology brings HIV-1 viral load measurement to Africa and other resource-poor countries. Primagen is expanding its product portfolio in the areas of drug toxicity and from virus discovery, with recent patent applications for duplex amplification and for two new viruses